Technology
Health
Biotechnology

Actinium Pharmaceuticals

$0.248
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0093 (3.90%) As of 12:07 PM EDT today
+$0.0093 (3.90%) Today

Why Robinhood?

You can buy or sell ATNM and other stocks, options, ETFs, and crypto commission-free!

About ATNM

Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Read More Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.

Employees
30
Headquarters
New York, New York
Founded
1993
Market Cap
28.44M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
519.21K
High Today
$0.2499
Low Today
$0.24
Open Price
$0.245
Volume
247.82K
52 Week High
$0.8651
52 Week Low
$0.23

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2013 IPO
US

ATNM Earnings

-$0.07
-$0.06
-$0.05
-$0.04
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.